Lv1
30 积分 2024-11-22 加入
IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases
2天前
已完结
Overexpression of an Engineered SERPINB9 Enhances Allogeneic T-cell Persistence and Efficacy
3个月前
已完结
Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study
3个月前
已完结
Immunologic monitoring with Orthoclone OKT3 therapy
3个月前
已关闭
Teclistamab-Induced Remission in Refractory Systemic Lupus Erythematosus
4个月前
已完结
Achievable but elusive: LLDAS and DORIS remission in clinical trials of belimumab
4个月前
已完结
Targeting fibroblast activation protein (FAP): advances in CAR-T cell, antibody, and vaccine in cancer immunotherapy
5个月前
已完结
Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas
5个月前
已关闭
Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas
5个月前
已关闭
Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas
5个月前
已关闭
皖公网安备34019202002308
